Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified: early-phase trial registry
6 of 9 indexed Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 6 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified: 9 US clinical trials tracked, 6 recruiting.
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Fred Hutchinson Cancer Center, running 2 of these trials.
Enrollment posture brief
Registry condition recurrent-diffuse-large-b-cell-lymphoma-not-otherwise-specified
OPEN 6 | RECR 67% | LATE 0 | EARLY 9 | RANK #1916 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified lists 6 open slots (67% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified is recruiting above its size-band peers.
6 of 9 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified research.
Fred Hutchinson Cancer Center accounts for 2 of 9 trials (22.2%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trials plan to enrol fewer than 100 people.
Median target enrolment is 27 among the 9 trials that report a genuine target (sentinel values excluded). 8 of those (88.9%) plan for fewer than 100 participants.
-
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified research is mostly interventional.
9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
National Cancer Institute (NCI)
NCT06649812
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
Mayo Clinic
NCT06834373
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
David Bond, MD
NCT05821088
ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
Fred Hutchinson Cancer Center
NCT07098364
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
University of Washington
NCT06784726
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Joseph Tuscano
NCT06905509
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Fred Hutchinson Cancer Center
NCT05359211
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma
Northwestern University
NCT05202782
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Mayo Clinic
NCT05507541
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified page
9 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Fred Hutchinson Cancer Center sponsors the most Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trials on record, review their full trial history before evaluating a specific study. See Fred Hutchinson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified condition card totals 9 registered trials; most-linked intervention Computed Tomography; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.